S&P 500   3,957.15 (-0.16%)
DOW   33,671.60 (-0.33%)
QQQ   283.87 (+0.01%)
AAPL   143.94 (+0.90%)
MSFT   246.44 (-0.39%)
META   116.46 (+0.98%)
GOOGL   93.29 (-0.45%)
AMZN   89.57 (-0.86%)
TSLA   180.30 (+3.96%)
NVDA   172.75 (+0.62%)
NIO   12.81 (-4.47%)
BABA   92.30 (-1.99%)
AMD   69.46 (-1.43%)
T   19.17 (+0.26%)
MU   55.46 (+0.47%)
CGC   2.93 (-5.18%)
F   13.21 (+0.69%)
GE   82.08 (-1.85%)
DIS   93.90 (+1.46%)
AMC   5.85 (-3.62%)
PYPL   74.16 (-0.08%)
PFE   51.84 (+0.12%)
NFLX   323.54 (+4.28%)
S&P 500   3,957.15 (-0.16%)
DOW   33,671.60 (-0.33%)
QQQ   283.87 (+0.01%)
AAPL   143.94 (+0.90%)
MSFT   246.44 (-0.39%)
META   116.46 (+0.98%)
GOOGL   93.29 (-0.45%)
AMZN   89.57 (-0.86%)
TSLA   180.30 (+3.96%)
NVDA   172.75 (+0.62%)
NIO   12.81 (-4.47%)
BABA   92.30 (-1.99%)
AMD   69.46 (-1.43%)
T   19.17 (+0.26%)
MU   55.46 (+0.47%)
CGC   2.93 (-5.18%)
F   13.21 (+0.69%)
GE   82.08 (-1.85%)
DIS   93.90 (+1.46%)
AMC   5.85 (-3.62%)
PYPL   74.16 (-0.08%)
PFE   51.84 (+0.12%)
NFLX   323.54 (+4.28%)
S&P 500   3,957.15 (-0.16%)
DOW   33,671.60 (-0.33%)
QQQ   283.87 (+0.01%)
AAPL   143.94 (+0.90%)
MSFT   246.44 (-0.39%)
META   116.46 (+0.98%)
GOOGL   93.29 (-0.45%)
AMZN   89.57 (-0.86%)
TSLA   180.30 (+3.96%)
NVDA   172.75 (+0.62%)
NIO   12.81 (-4.47%)
BABA   92.30 (-1.99%)
AMD   69.46 (-1.43%)
T   19.17 (+0.26%)
MU   55.46 (+0.47%)
CGC   2.93 (-5.18%)
F   13.21 (+0.69%)
GE   82.08 (-1.85%)
DIS   93.90 (+1.46%)
AMC   5.85 (-3.62%)
PYPL   74.16 (-0.08%)
PFE   51.84 (+0.12%)
NFLX   323.54 (+4.28%)
S&P 500   3,957.15 (-0.16%)
DOW   33,671.60 (-0.33%)
QQQ   283.87 (+0.01%)
AAPL   143.94 (+0.90%)
MSFT   246.44 (-0.39%)
META   116.46 (+0.98%)
GOOGL   93.29 (-0.45%)
AMZN   89.57 (-0.86%)
TSLA   180.30 (+3.96%)
NVDA   172.75 (+0.62%)
NIO   12.81 (-4.47%)
BABA   92.30 (-1.99%)
AMD   69.46 (-1.43%)
T   19.17 (+0.26%)
MU   55.46 (+0.47%)
CGC   2.93 (-5.18%)
F   13.21 (+0.69%)
GE   82.08 (-1.85%)
DIS   93.90 (+1.46%)
AMC   5.85 (-3.62%)
PYPL   74.16 (-0.08%)
PFE   51.84 (+0.12%)
NFLX   323.54 (+4.28%)
NYSE:IBER

Ibere Pharmaceuticals - IBER Stock Forecast, Price & News

$10.05
0.00 (0.00%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$10.05
$10.05
50-Day Range
$9.91
$10.05
52-Week Range
$9.68
$10.05
Volume
6,746 shs
Average Volume
24,666 shs
Market Capitalization
$173.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Ibere Pharmaceuticals

Ibere Pharmaceuticals does not have significant operations. It focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Philadelphia, Pennsylvania.

Receive IBER Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ibere Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IBER Stock News Headlines

See More Headlines
Receive IBER Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ibere Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IBER Company Calendar

Last Earnings
11/14/2022
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/13/2023

Industry, Sector and Symbol

Industry
Holding & other investment offices
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Net Income
$1.56 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
$0.09 per share
Book Value
($0.63) per share

Miscellaneous

Free Float
13,800,000
Market Cap
$173.36 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Osagie O. Imasogie Esq. (Age 60)
    Chairman & CEO
  • Ms. Lisa M. Gray CPA (Age 57)
    CPA, CVA, CFO, Exec. VP & Director
  • Mr. Zoltan Kerekes J.D. (Age 56)
    COO, Exec. VP & Director













IBER Stock - Frequently Asked Questions

How have IBER shares performed in 2022?

Ibere Pharmaceuticals' stock was trading at $9.72 at the beginning of the year. Since then, IBER shares have increased by 3.4% and is now trading at $10.05.
View the best growth stocks for 2022 here
.

Are investors shorting Ibere Pharmaceuticals?

Ibere Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totaling 4,100 shares, an increase of 10.8% from the October 31st total of 3,700 shares. Based on an average trading volume of 30,800 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company's stock are sold short.
View Ibere Pharmaceuticals' Short Interest
.

When is Ibere Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 13th 2023.
View our IBER earnings forecast
.

How were Ibere Pharmaceuticals' earnings last quarter?

Ibere Pharmaceuticals (NYSE:IBER) posted its quarterly earnings results on Monday, November, 14th. The company reported $0.06 earnings per share for the quarter.

What is Ibere Pharmaceuticals' stock symbol?

Ibere Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "IBER."

Who are Ibere Pharmaceuticals' major shareholders?

Ibere Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include First Trust Capital Management L.P. (3.15%), Saba Capital Management L.P. (1.91%), Cubist Systematic Strategies LLC (0.41%), Mizuho Securities USA LLC (0.23%), Virtu Financial LLC (0.15%) and Capstone Investment Advisors LLC (0.14%).

How do I buy shares of Ibere Pharmaceuticals?

Shares of IBER stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ibere Pharmaceuticals' stock price today?

One share of IBER stock can currently be purchased for approximately $10.05.

How much money does Ibere Pharmaceuticals make?

Ibere Pharmaceuticals (NYSE:IBER) has a market capitalization of $173.36 million.

How can I contact Ibere Pharmaceuticals?

Ibere Pharmaceuticals' mailing address is 2005 MARKET STREET SUITE 2030, PHILADELPHIA PA, 19103. The official website for the company is www.iberepharma.com. The company can be reached via phone at 267-765-3222.

This page (NYSE:IBER) was last updated on 12/9/2022 by MarketBeat.com Staff